Listicle
- Sartorius Stedim’s first half revenue for 2024: EU1.37 billion.
- Revenue estimate by analysts: EU1.38 billion.
- Underlying EBITDA for the first half: EU387 million.
- Company adjusted its full-year 2024 guidance.
- Now expects full-year sales to be at the prior-year level.
- Forecasts full-year underlying EBITDA margin to be between 27% and 29%.
- Previous forecast for full-year underlying EBITDA margin was over 30%.
- No changes to medium-term targets up to 2028.
- First half underlying net profit: EU165 million.
- Analyst recommendations: 11 buys, 4 holds, 1 sell.
A look at Sartorius Stedim Biotech Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 2 | |
| Growth | 3 | |
| Resilience | 2 | |
| Momentum | 2 | |
| OVERALL SMART SCORE | 2.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, Sartorius Stedim Biotech shows a mixed long-term outlook. With a Growth score of 3, the company is positioned well for expansion and development. This suggests that Sartorius Stedim Biotech may have potential for increasing its market presence and revenue over time. However, other factors such as Value, Dividend, Resilience, and Momentum all received scores of 2, indicating a more moderate outlook in these areas. This means that while the company may have growth potential, it may face challenges in terms of value, dividends, resilience to market changes, and momentum in the near future.
Sartorius Stedim Biotech develops and manufactures laboratory technologies and equipment for the pharma and food industries, as well as for public research institutes and laboratories. With a focus on serving these sectors, the company plays a crucial role in advancing scientific research and production processes. The mixed Smartkarma Smart Scores for Sartorius Stedim Biotech suggest a nuanced outlook, with opportunities for growth but also areas that may require attention to fully capitalize on its potential in the long term.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
